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Aim of the study 
1. To study the epidemiological characteristics of the disease in 
India 
2. To analyze the surgical data and present the outcome. 
3. Describe the pattern of recurrence and salvage modality for 
recurrence. 
4. To find out the optimal management strategy for this rare 
disease 
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Introduction 
 
               Aggressive Fibromatosis also known as Desmoid tumors is a 
monoclonal disorder affecting the musculoaponeurotic tissues. It is 
relatively a rare neoplasm with a frequency of about <3% of all soft 
tissue tumors and annual incidence of about 0.2 to 0.5 per 100000 
population. Exact etiology of aggressive fibromatosis is currently 
unknown. It is probably multifactorial with hormonal, genetic and 
trauma playing their parts. They are locally infiltrative and never 
metastasize but have a tendency for multiple recurrences. The 
morbidity caused by this lesion is due to local destruction of tissues 
and occasional death has been reported(2). 
 
 
          Aggressive Fibromatosis are heterogenous group of tumors 
which share similar clinical, histological and molecular genetic feature. 
But each type has some subtle and unique feature which distinguishes 
it from others. Due to the relative rarity of this tumor and their 
enigmatic clinical behavior, treatment for fibromatosis has not been 
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optimized. In this article we will be discussing about our experience 
with deep fibromatosis. 
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Materials and methods 
  A retrospective analysis of our data over a period of 13 
yrs (between 1998 and 2010) was done. There were 33 patients with a 
diagnosis of deep fibromatosis in our records which included 
abdominal, intra-abdominal and extra abdominal. In 28 patients a wide 
excision of the lesion was performed with curative intent. Adjuvant 
radiotherapy was given for 4 patients and systemic therapy in the form 
of tamoxifen was given for 4 patients. 
  Information regarding epidemiological characteristics of 
the disease, surgical procedure performed postoperative margin status 
on histopathological examination, adjuvant treatment given, 
recurrences in the follow-up period, pattern of recurrence and salvage 
modality for recurrence were collected for analysis. 
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Observation and Analysis 
 
                  The disease and its natural course to some extent were 
described 170 years ago. Although numerous researchers have 
dedicated their time to acquire more knowledge about this disease, 
every aspect of this disease beginning form etiology to management is 
full of controversies. The enigma of fibromatosis will continue to 
haunt the researchers for some more time as new findings (like ERβ) 
lead to more questions than answering the older ones. In this analysis 
we will concentrate on the Indian perspective about the disease and 
explore the lacunae in the literature. 
 
Demographic trend 
                    There were 18 female patients & 15 male patients a ratio 
of around 1.2:1. In western literature a female preponderance in the 
ratio of 3:1 is described. In pediatric age group fibromatosis is 
extremely rare and has a male preponderance. We had 5(15%) 
pediatric patients and 4 of them were male. 
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Sex distriburion
18
15
 
 The mean age of presentation is 25.8, ranging from 7 to 64. The 
number of swelling at presentation ranged from one to 6. The size of 
the tumor ranged from 3cms to 20cms, mean 9cms. There were 21 
primary tumors and 12 recurrent tumors. The average duration of 
presenting symptom was more with recurrent tumors than with primary 
tumors. 
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Enzeinger & Weiss's classification which is widely accepted is 
utilized for classifying deep fibromatosis in this article. 
Table 1. Deep(Musculoaponeurotic) Fibromatosis - Enzeinger & 
Weiss  
Extra- abdominal fibromatosis                          28 
Abdominal fibromatosis 1 
 
 
       Intra - Abdominal fibromatosis 
Pelvic fibromatosis 1 
Mesentric fibromatosis 3 
Mesentric fibromatosis in Gardner syndrome 0 
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Table 2. Site distribution  of Extra abdominal fibromatosis 
         Shoulder                       3 
       Arm        9 
       Fore arm         2 
Gluteal          2 
Thigh         5 
Leg & foot        3 
Head & Neck                              2 
Lower limb        2 
             
               Fibromatosis has a predilection to affect muscles around the 
shoulder and pelvic gridle followed by other locations. In our series, 
there were 12 tumors around the shoulder gridle and 9 around the 
pelvic gridle. Site distribution in our series is in concordance with 
western literature except there were no cases associated with Gardners 
syndrome, which is rare in India.  
 
               Demographic pattern of the disease in our series with regards 
to age range, location & site distribution is in concordance with the 
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western literature. But there is an increased male sex and pediatric age 
group incidence in our series. We could not find any reason for this 
increased incidence. Whether this constitutes a different demographic 
trend in India for this disease can be confirmed only when data from 
different parts of the country is pooled and analyzed. Although only 
one patient was diagnosed to have abdominal fibromatosis, we believe 
the incidence to be more. The lower incidence might be due to 
different referral patterns than due to real difference the demographic 
trend. 
 
 Management          
  We discuss all our cases in multidisciplinary tumor board & 
offer surgical excision as primary treatment for operable tumors and 
radiation or systemic therapy for inoperable tumors. In few of these 
patients histology can be inconclusive since fibromatosis contains few 
neoplastic cells and more collagen. In such cases a decision to operate 
is taken after considering the clinical and imaging findings. 
   26 patients with extra abdominal fibromatosis, 1 with 
abdominal and 1 with mesenteric fibromatosis underwent surgery. 2 
mesenteric, 1 head & neck and 1 pelvic fibromatosis were inoperable 
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due to extensive local infiltration. 2 patients refused any form of 
therapy. 
    The details of 26 patients with extremity, 1 with abdominal and 1 
with mesenteric fibromatosis who had undergone primary surgical 
excision are given in  
table 3. 
 
Table 3.Details of patients who had under gone surgery for 
Aggressive fibromatosis in our department 
Age  
     Range   7 – 42 
     Median     30 
Sex  
     Male      12 
     Female      16 
Mean Size      9.5 cm 
Site  
       Shoulder     3 
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       Arm      9 
       Forearm & Hand     2 
       Gluteal     2 
       Thigh     5 
       Leg & Foot     3 
       Anterior abd wall     1 
       Head & Neck     1 
       Mesentric     1 
       Lower limb     1 
Presentation  
       Primary    17 
       Recurrent    11 
 
 12 
  The mean tumor size in the surgical group was 9.5cms. In 
all but one patient limb salvage was done successfully. One patient 
who had undergone limb salvage surgery along with vascular resection 
has to be amputated as she developed vascular graft infection. Surgical 
excision constituted a wide monobloc excision with 1cm margin. 
Clearance near vital structures was conservative to preserve maximum 
function. All oncological principles followed in limb salvage surgeries 
done for sarcomas were adhered to. Surgical procedure ranged from 
wide excision of the tumor to complex muscle group excision. Details 
of the limb salvage procedures undertaken are given in table 4. 
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Table 4: Details of the surgical procedure 
Surgical procedure No of patients 
Wide monobloc  excision 19 
Scapulectomy 3 
Centralisation of Ulna 2 
Excision of metatarsals with bone 
grafting 
2 
Laparotomy  and excision 1 
Amputation 1 
 
Abdominal Fibromatosis- Paucity of data 
                         Only one of our patients had abdominal fibromatosis. 
This patient was quite young (14 yrs) and was not associated with 
pregnancy. She was treated with wide excision and no adjuvant was 
given. She is disease free till now. This fact is surprising as abdominal 
fibromatosis has much higher incidence than what is seen in our series. 
This might be due to different referral patterns than due to real 
difference the demographic trend. 
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Intra abdominal fibromatosis - Hig risk site for inoperability  
           In our series there were 4 patients who had intra abdominal 
fibromatosis - 2 mesentric, 1 retroperitoneal and 1 pelvic. In only one 
of these patients we were able to achieve complete surgical excision. 
This reiterates the fact that intraabdominal fibromatosis is high risk 
region for inoperability. But surgical exploration with intent to 
completely excise the tumor should be the aim since it is associated 
with long term local control. One of our patients with retroperitoneal 
fibromatosis in whom a complete excision was possible is disease free 
until now although no adjuvant was given to him. 1 patient with 
mesenteric fibromatosis who was put on tamoxifen after finding his 
disease inoperable is having a stable disease for the past 5 years. 
 
 
Recurrences and pattern of recurrence 
   We experienced 12 recurrences (40% recurrence 
rate) in our series. All recurrences were salvaged by revision surgery. 
Various variables taken up for analysis of recurrences are given in 
table 5. 
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Table 5. Comparison between recurrent and disease free group   
 Disease free 
group 
Recurrence 
group 
Time taken to 
recur 
No Patients 22 6  
Site Not siginificant Not siginificant  
Size 9cm 9.5cm  
Median Age  29 35  
Number of 
primary tumor 
   
        Single 19 4 16 months 
        Multiple 3 2 13 months 
Status of 
margin 
   
       Positive 2 4 15 months 
       Negative 20 2 11 months 
Presentation    
       Primary 15 2 13 months 
       Recurrent 7 4 16 months 
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                  In the surgical group there were 5 positive margins and 1 
close margin. Median follow-up time in our series is 5 yrs. There were 
12 recurrences in the surgical group an incidence of 40%. All our 
recurrences were salvaged by revision surgery. 4 patients were offered 
adjuvant radiation. All inoperable tumors were offered tamoxifen.  
                  
          In our series sex, site of the tumor, multiplicity of the tumor at 
presentation or size of the tumor did not influence recurrence. 
Presentation - primary vs recurrent was associated with increased 
recurrence rate, 24% of primary & 56% of recurrent tumors 
experienced recurrence. Status of the margin, positive vs negative had 
a positive impact on recurrence, 10% in disease free group and 66% in 
recurrent group had positive margins.   
 
                The propensity of aggressive fibromatosis to locally recur is 
related to its infiltrative nature, which makes it difficult for the surgeon 
to grossly identify the true extent of disease. These tumors lack a 
pseudocapsule and display nonpalpable diffusion along muscle bundles 
and fascial planes. This may justify the high recurrence rate of the   
disease after adequate surgery. Posner et al, Goy et al and Spear et al 
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identified positive resection margins as the most important 
Independent predictive factor of local recurrence. But in a study by 
Merchant et al and in few other studies positive margin does not affect 
the outcome adversely. Gronchi et al speculates that the recurrence rate 
highly depends on inherent characteristics of the disease, which might 
be more or less aggressive on its own, so that it might recur or not 
rather independent of the fine quality of surgery.  
 
               In Gronchi et al's series, patients with large tumors located at 
the extremities or girdles had a higher risk of recurrence, regardless of 
whether they were excised with positive or negative resection margins. 
We did not find any such association between site and recurrence. 
 
              The most intriguing aspect of our recurrence pattern is the 
time to recur. Although positive margin in our series was associated 
with high recurrence rate, the duration taken for the tumor to recur in 
both the positive margin group and negative margin group did not 
show any significant difference. The number of tumor at presentation, 
single vs multiple and the presentation, primary vs recurrent, also did 
not show any significant difference in the time taken to recur. 
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Although we could not find any literature evidence to support this fact, 
we believe this fact reiterates that recurrences in fibromatosis may be 
more influenced by the biology of the disease. 
 
 Pattern of recurrence in fibromatosis can also be quiet different 
from other tumors. Recurrences can be within the surgical field or also 
away from it. In our series one patient who had a tumor in the origin of 
coracho brachialis after surgical excision experienced recurrence at 
lower end of the muscle about 10 cm away from the primary tumor and 
another recurrence in pectoralis major muscle. Whether this is due to 
intra muscular microscopic infiltration of the tumor along the muscle 
spindles or a genetic field defect in the affected muscles is unknown. 
In few patients the recurrences can be just outside the radiation field. 
One of our patients experienced a recurrence just outside the radiation 
field.  
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Adjuvant therapy 
         4 of our patients received adjuvant RT out of which 1 
experienced recurrence which was salvageable by revision surgery. 
Recommendations for adjuvant radiation have not been standardized. 
As most of our patients are young and all our recurrences are 
salvageable by revision surgery we do not offer adjuvant RT routinely 
to avoid long term complications of RT. We recommend it for multiple 
recurrences, positive margin and multiple tumors at presentation to 
avoid mutilating salvage surgery. 
 
  We offer Tamoxifen to all inoperable tumors. One of our 
patients with mesenteric fibromatosis is having stable disease for the 
past 5 years. We could not come to any conclusion on the efficacy of 
tamoxifen since all other patients are lost to follow-up. We also offer 
tamoxifen in adjuvant setting for patients who had experienced 
multiple recurrences. The efficacy of tamoxifen in adjuvant setting 
could not be analysed in our patients as the number is very small. We 
are yet to find a clinical situation in which cytotoxic chemotherapy is 
to be considered. 
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Multicentric Fibromatosis – Describing a new entity 
  Fong et al has described an entity where multiple lesions 
are found typically confined to one anatomical region of the body. In 
most cases the second growth is found proximal to the first growth. 
This is found in 5% of the patients diagnosed to have extra abdominal 
fibromatosis. 
 
              Although multicentric fibromatosis confined to one 
anatomical region is a known entity, we describe a new hitherto 
undescribed non random pattern of distribution of multicentric 
extremity fibromatosis.  
 
  Two male patients presented with multiple fibromatosis of 
lower limb distributed in gluteus muscles, quadriceps, muscles of 
popliteal fossa and a lesion in between metatarsals in the foot. One 
patient underwent wide excision of all lesion and is disease free for the 
past one year. The other patient, who has had the disease for the past 
10 years, refused any form of treatment. In both patients the tumors 
were around the hip and knee joint and both of them had the disease 
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for more than 10 years. Fong et al's observation of second growth 
arising proximal to the first one was not seen in both patients. The new 
lesions arose both proximal and distal to the index lesion. 
 
                      One female patient had multiple lesions in the upper limb 
distributed along Pectoralis major, Biceps, Corachobrachialis and 
between the metacarpals. These tumors were found arising around the 
shoulder and knee joint and again the new lesions arose both proximal 
and distal to the index lesion. 
 
                     In all the three patients the lesions were separated widely 
and found to cross the joints as well. This fact rules out the possibility 
of skip metastasis or a contiguous spread from the index lesion. The 
nonrandom pattern of distribution especially the tumors arising 
between the metacarpals and metatarsal is striking and is not possible 
with any known local infiltrative patterns. 
 
                   We believe the muscle groups involved in this form of 
fibromatosis acquires a genetic defect and some other environmental or 
hormonal factor makes the tumors to manifests itself at a later age. 
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Since it does not affect the other limbs or other muscle groups of the 
body the environmental insult probably happens at the time of limb 
development. Molecular analysis of the involved muscles and adjacent 
muscles might shed more light in this matter. 
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Literature Review 
Etiology and Genetics 
 
          Exact etiology of aggressive fibromatosis is currently unknown. 
It is probably multifactorial with hormonal, genetic and trauma playing 
their parts. Trauma as causative factor is controversial. Although there 
are many anecdotal reports suggesting trauma as an important 
causative factor it remains to be established. The long standing 
controversy regarding the nature of this lesion, whether neoplastic or 
reactive, appears to be answered with consistent cytogenetic 
abnormalities found in these tumors.46% of deep tumors and 10% of 
superficial tumors show trisomies 8 & 20 and loss of 5q(1,3). These 
findings prove it to be a true neoplasm rather than a reactive lesion. 
 
Beta catenin pathway 
 
Sporadic as well as FAP associated fibromatosis show elevated 
levels of beta catenin levels. Mutations in APC gene leading to 
abnormal levels of beta catenin resulting in a growth advantage is the 
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central abnormality in most of these tumors. This pathway is known as 
WNT –APC-Beta –Catenin signaling cascade.  
 
  What ever may be the genetic abnormality it appears to 
remain stable through out the life, evident from the fact that sarcomas 
do not arise from fibromatosis even in patients with long standing 
disease. Beta catenin stabilizing mutations, apart from fibromatosis 
have been found in other benign conditions like Pilomatrixoma and 
Hepatoblastoma. This suggests that fibromatosis is essentially a benign 
condition although it mimicks malignancy in many ways. 
 
Fibromatosis and Estrogen receptors 
       It is a well known fact that some of these tumors 
respond to Tamoxifen but estrogen receptor has been found only in 
few of these tumors. Immunohistochemical analyses have consistently 
shown these tumors to be negative for ERα and c- Kit. But this 
neoplasm does have an hormonal influence ,especially to estrogen . 
This is suggested by the following  facts  
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1. Female preponderance,  
2. Growth rate increases during pregnancy and    
3. Anecdotal reports of complete regression of these tumors with 
Tamoxifen. 
 
  Recently in 1996 the presence of second estrogen receptor has 
been discovered and named as ERβ, the traditional receptor has been 
named ERα. Fibromatosis has shown to express more of ERβ and this 
explains the clinical efficacy of antiestrogens even in the absence of 
conventional estrogen receptor. Reports of this tumor responding to 
imatinib may not be due to  c- kit mutations. 
 
Clinical presentation 
             Classical presentation is a deep seated mass that is painless and 
slow growing. It may cause restriction of movements and can affect 
the bone as well. They are locally infiltrative and never metastasize but 
have a tendency for multiple recurrences. The morbidity caused by this 
lesion is due to local destruction of tissues by direct infiltration and 
pressure effects. Occasional death has been reported due to 
involvement and destruction of vital organs. No paraneoplastic 
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conditions have ever been described, fibromatosis coexist with the host 
peacefully. 
 
               Aggressive fibromatosis commonly affects shoulder followed 
by chest wall, back, thigh and head and neck.  Fibromatosis of head 
and neck is particularly aggressive causing massive destruction of soft 
tissue and bone often resulting in fatal outcome.  
 
 Aggressive fibromatosis is more common in females, most 
authors report a male to female ratio of 3:1. However in children the 
sex incidence is equal. Desmoid tumors can occur during any age but 
they are extremely uncommon during the extremes of the age. Most 
common age group to be affected is between 10 and 40. 
 
             Histologically these lesions appear benign but have an 
aggressive clinical behaviour. Characteristic microscopic finding are 
abundant collagen with uniform appearing spindle shaped cells which 
are widely distributed and have little or no cell to cell contact. Mitoses 
are few in number. At the periphery the tumor infiltrates into 
surrounding musculature.  
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Classification   
                 
             Reitamo et al classified these tumors into 4 major  clinical 
groups  
1. Juvenile – Extra abdominal location  with a predilection for 
young girls of less than 15 years. 
2.  Fertile – Abdominal in fertile females 
3.  Menopausal – Abdominal but with equal male and female 
incidence 
4.  Senescent – Both abdominal and extra abdominal with equal 
sex distribution 
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Recently Enzinger has classified these tumors more 
comprehensively into two major groups superficial and deep (Table 
1). 
 
             Table 1 
            Superficial(fascial)Fibromatosis 
  Palmar fibromatosis(Dupuytren's disease) 
            Plantar fibromatosis(Ledderhose'disease) 
            Penile fibromatosis(Peyronie's disease) 
            Knuckle pads 
            Deep(Musculoaponeurotic) Fibromatosis 
      Extra- abdominal fibromatosis 
            Abdominal fibromatosis 
            Intra abdominal fibromatosis 
                Pelvic fibromatosis 
                Mesentric fibromatosis 
                Mesentric fibromatosis in Gardners syndrome 
 
     Superficial fibromatosis arise from fascia and aponeurosis , are 
slow growing and small. They rarely involve the deep structures. The 
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natural course of disease have two phases, first is a cellular 
proliferative phase followed by a late collagenous  contractile phase. 
Deep fibromatosis are rapidly growing tumor and often attain a large 
size. Their biological behavior is aggressive compared to superficial 
fibromatosis. The natural course of fibromatosis is still an enigma. The 
disease manifestation ranges from spontaneous regression in some 
patients to multiple recurrences in some. Some authors have described 
a stable phase for the disease during which the size of the tumor does 
not change, this period ranges from 6 months to 3 years.  
 
Extra abdominal fibromatosis   
           Extra abdominalfibromatosis is synonymous with aggressive 
fibromatosis, desmoid tumor and extra abdominal desmoid tumor(4). It 
arises from connective tissue of muscle and the overlying fascia and 
aponeurosis.  It is most common in patients between puberty and 40 
years of age. 5% of the patients are below 10 yrs of age. Common 
clinical presentation is a painless deep seated mass. Decreased 
mobility of the affected joint may occur. 
           Aggressive fibromatosis affected patients have multiple minor 
bony abnormalities. This may be present in upto 80% of patients. This 
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includes cortical thickening, exostoses and areas of cystic translucence 
or compact islands in the femur( or both). 
  
         In the shoulder and neck region it most commonly affects the 
deltoid,scapular region,supraclavicular and posterior cervical triangle 
from where it may descend into anterior or posterior portion of the 
axilla and arm. 
 
        Fibromatosis of the pelvic gridle primarily affects the gluteus 
muscle, in the thigh it affects quadriceps and muscles of popliteal 
fossa. Hand and foot are rarely affected. 
          Although Enzinger & Weiss has grouped extra abdominal 
fibromatosis under one umbrella there may be different sub groups 
with distinct clinical behavior. Two of them are Head & Neck 
fibromatosis and Pediatric fibromatosis.  
 
Pediatric fibromatosis 
         The overall incidence of AF in childhood is estimated at 2–4 new 
diagnoses per 1 million per year. Childhood AF has an age distribution 
peak at approximately 8 years (range, 0–19 years) with a slight male 
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predominance.more than one third of them occur in head and neck 
region(6).  Surgery is the recommended treatment and the role of 
adjuvant therapies are yet to be standardized. Late toxicity and 
occurrence of second malignancy should be taken into consideration 
when prescribing adjuvant treatment. 
 
Head and neck fibromatosis 
       Head and neck region is affected in upto 23% of patients with 
extraabdominal fibromatosis. It usually affects younger patients. The 
soft tissues of the neck are most commonly affected followed by oral 
cavity, scalp, paranasal sinuses and orbit. This subtype particularly 
aggressive and is capalble of producing massive destruction of 
adjacent bone and erosion of base of the skull(5). They occasionally 
encroach trachea and may result in death. 
 
Multicentric fibromatosis 
      Fong et al has described an entity where multiple lesions are found 
typically confined to one anatomical region of the body. In most cases 
the second growth is found proximal to the first growth. This is found 
in 5% of the patients diagnosed to have extra abdominal fibromatosis. 
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Rarely co existence of abdominal and extra abdominal fibromatosis 
has been found in the same patient. 
 
Abdominal fibromatosis 
      Abdominbal fibromatosis occurs in young, gravid  or parous 
women during gestation or more frequently during the first year 
following child birth(19,20&30). The tumor arises from 
musculoaponeurotic structures of abdominal wall, especially rectus 
and internal oblique and their fascial coverings. There may be a 
solitary lesion or multiple lesions(8).  Endocrine etiology is strongly 
believed because of its frequent association with pregnancy and few 
reports of spontaneous regression with menopause. Wide local 
excision is the treatment of choice but multiple recurrences are 
common.  
 
Intraabdominal fibromatosis 
      The intraabdominal fibromatosis includes a group of closely 
related lesions rather than single entity which have similar histology 
but distinct location and clinical behavior. They include Pelvic 
fibromatosis, Mesentric fibromatosis and fibromatosis of Gardners 
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syndrome. These tumors share similar clinical, histological and 
molecular genetic features but each type has some subtle and unique 
feature which distinguishes it from others. 
 
 Mesentric fibromatosis 
        Fibromatosis is the most common tumor of the mesentry and 
occounts for 8% of all fibromatoses. Most cases are sporadic but few 
are associated with FAP/Gardners syndrome. Small bowel mesentry is 
the most common location  but it may affect iliocolic mesentry, 
gastrocolic ligament, omentum or retroperitoneum. Clinically it is 
difficult to distinguish it from retroperitoneal fibrosis and sclerosing 
mesenteritis. Other important differential diagnosis is GIST. Excision 
is the treatment of choice but is often difficult due to irregular growth 
and attachment to mesentry. Other alternatives like anti estrogens, 
cytotoxic chemotherapy and radiotherapy have been used with variable 
results. 
Mesentric fibromatosis associated with Gardners syndrome 
         The incidence of desmoid tumors with poloposis coli is around 
10 to 15%. It usually occurs 1 to 2 years after excision of disease 
portion of the colon. These lesions are the most common cause of 
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death in patients with polyposis coli after colectomy(7,9,10&11). 
Treatment is similar to mesenteric fibromatosis without gardners 
syndrome but multiple recurrences are common. 
 
Pelvic fibromatosis 
       Pelvic fibromatosis occurs in young females between 20 and 35 
and often unrelated to gestation or child birth. They are present as slow 
growing painless pelvic masses. Clinically they mimic ovarian masses 
or mesenteric cyst. Large tumors encroach on urinary bladder,vagina 
or rectum. They may cause hydronephrosis. Surgical treatment is the 
standard one. A suprapubic approach alone or in combination with an 
inguinal approach is recommended. Hemipelvectomy may be required 
sometimes to achieve R0 resection, instead of this morbid procedure a 
conservative approach with tamoxifen and NSAIDs have been tried 
with some success. 
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Pathology 
 On gross examination, the tumours are always confined to the 
musculature and the overlying aponeurosis or fascia. Their size varies 
from 5 to 20 cm. The tumours are firm, cut with a gritty sensation, and 
on crosssection reveal a glistening white, coarsely trabeculated surface 
resembling scar tissue.  
 
 Microscopically, desmoid tumours are poorly circumscribed, 
infiltrating the surrounding tissue. The proliferation consists of 
elongated, slender, spindle-shaped cells of uniform appearance. The 
tumour cells are surrounded and separated from one another by 
abundant collagen, with little to no cell-to-cell contact. The cells lack 
atypia, but cellularity may vary within the same lesion. Nuclei are 
small, pale-staining, and sharply defined. One to three small nucleoli 
are usual. 
 
 Ultrastructurally, desmoid tumours consist of a uniform 
population of elongated fibroblast-like cells, often terminating in long, 
slender processes. Most nuclei are rounded or oval, but some cells 
show prominent nuclear indentations or clefts. There is a prominent 
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rough endoplasmic reticulum, partly dilated, containing granular or 
fibrillary material within the dilated spaces. The cytoplasm has a small 
number of mitochondria, a prominent Golgi apparatus, free ribosomes, 
and occasional pinocytotic vesicles and microtubules. Some cells 
contain intracytoplasmic 
bundles of actin-type microfilaments, and incomplete or clumped basal 
lamina along the cell borders, all features characteristic of 
myofibroblasts. The stroma contains considerable amounts of collagen 
and ground substance. 
 
Imaging of Desmoid Tumors  
   Radiographs may be normal or may show a nonspecific 
soft-tissue mass. Calcification is uncommon. Underlying bone 
involvement is seen in 6%–37% of patients, typically with pressure 
erosion and cortical scalloping but without invasion of the medullary 
canal .Bone scintigraphy usually demonstrates increased uptake on 
blood pool and static images. Angiograms are variable in appearance, 
often showing marked hypervascularity, although some lesions 
demonstrate no vascular blush. 
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  CT scans of the deep fibromatoses are also usually 
nonspecific. Lesions may be hypoattenuating relative to skeletal 
muscle but are typically isoattenuating or even hyperattenuating. The 
latter finding may be related to lesions with more extensive collagen. 
Lesions usually demonstrate enhancement after intravenous 
administration of iodinated contrast material; the enhancement is 
sometimes marked(18). Owing to the infiltrative growth pattern and the 
attenuation similar to that of skeletal muscle, the margins of the lesion 
are often indistinct at CT unless it is separated from normal tissue by a 
fat plane. Subtle pressure erosions of bone are often better evaluated on 
radiographs owing to beam-hardening artifact at CT. 
  The best imaging modality for evaluation and staging of 
the deep fibromatoses is MR imaging. Extraabdominal desmoid tumors 
are typically intermuscular lesions, although muscle invasion is 
common. In addition, linear extension along fascial planes is a frequent 
manifestation and is uncommon with other soft-tissue neoplasms. The 
MR imaging pattern of the deep fibromatoses has been highly variable. 
The most common signal intensity pattern is heterogeneous, with 
intermediate signal intensity (similar to that of fat on T2-weighted 
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images and similar to that of skeletal muscle on T1-weighted images) 
seen with standard pulse sequences .The heterogeneous signal intensity 
pattern likely corresponds to the varying proportions of cellular tissue, 
myxoid tissue (high water content and high signal intensity on T2-
weighted images), and collagen (low signal intensity with all pulse 
sequences) in the lesion .Prominent low-signal-intensity bands are 
often seen with all pulse sequences and are likely related to the dense 
areas of collagen .Areas of low signal intensity with all pulse 
sequences are characteristic of fibromatosis but not specific for it. 
Other types of soft-tissue masses with prominent low signal intensity 
on T2-weighted images include giant cell tumor of tendon sheath (a 
localized form of pigmented villonodular synovitis), calcified masses, 
and malignancies such as fibrosarcoma or malignant fibrous 
histiocytoma .The deep fibromatoses typically demonstrate moderate to 
marked enhancement after administration of gadolinium contrast 
material, particularly in less collagenized and more cellular regions 
.Only 10% of lesions lack significant enhancement at MR imaging 
.Lesion margins at MR imaging may be well defined or infiltrative. 
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  MR imaging should be used for preoperative staging, 
particularly to evaluate for neurovascular and bone involvement. In 
extremity lesions, the entire limb should be imaged to rule out 
multicentric disease. MR imaging is also the best imaging modality to 
evaluate for postsurgical local recurrence. Recurrent deep fibromatosis 
shows intrinsic MR imaging characteristics similar to those of the 
original lesion. The site of recurrence is frequently at the lesion 
margins at areas of fascial extension where surgical resection is 
incomplete, leaving residual tumor. In patients who undergo radiation 
therapy or chemotherapy alone without surgery, MR imaging is useful 
in evaluating the effectiveness of therapy. Effective therapy (good 
lesion response) is indicated by a reduction in size and an increasing 
degree of low signal intensity on T2-weighted images, which reflects 
increased collagenization in response to therapy. 
Biopsy method  
 
           There have been only a few published  studies of single cases or 
relatively smallseries of desmoids examined by FNA, with some 
indicating its usefulness (Raab et al. 1993, Åkerman 2003) and others 
pointing out the pitfalls of occasional misinterpretation of 
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malignancies (Powers et al. 1994, Dey et al. 2004). The occasional 
over-diagnosis of sarcoma in desmoid tumors using FNA and the 
under-recognition of sarcomas falsely diagnosed as desmoids on FNA 
is reported by Åkerman et al.  
       The few reports of core needle biopsies in the preoperative 
diagnosis of desmoids suggest that it is a very useful technique (Serpell 
and Pitcher 1998, Ray- Coquard et al. 2003). The simplicity of the core 
needle biopsy technique, the almost constant representative material 
obtained in the hands of surgeons or others with experience, the 
abundance of material obtained that allows recognition of the 
histological characteristics and growth pattern, and the high degree of 
diagnostic accuracy all suggest that this technique is the diagnostic 
method of choice. FNA still has a role to play in the diagnosis of 
desmoids, particularly in cases with tumors located at sites that are in 
close proximity to major vessels or nerves, pleura and lungs, which 
would lead to unnecessary risks or complications when a core needle 
biopsy is used. 
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Management         
         Treatment for fibromatosis has not been optimized. Goals of the 
management are to attain local control with maximum preservation of 
function and cosmesis. But what constitutes adequate treatment is still 
elusive. As of today surgery forms the main stay of treatment and 
radiation has been used in adjuvant setting and for inoperable tumors. 
Cytotoxic chemotherapy,  NSAIDs and hormonal therapy has been 
used with varying success but the results are less predictable. 
 
  Surgery 
           Surgical treatment produces a local control of about 70% and an 
overall 5yr survival in excess of 90% in many series.  Surgical 
treatment for this lesion has considerable controversies. Local 
recurrence after surgical resection alone ranges from 40% to 60% in 
most series(15&16). Recurrences had been within the surgical field and 
also away from it. Some of the high risk factors associated with local 
recurrence are presentation – primary vs recurrent tumors and quality 
of surgical margin free vs close or positive. Positive surgical margin 
has been found to be a siginificant predictor of local recurrence in 
many series including that of Gronchi et al. But many other series have 
 42 
found equal recurrence rate with positive as well as negative surgical 
margin. In few series a positive margin is a predictor of local failure 
for recurrent lesions but not for primary tumors. Extent of resection 
required for these lesions is yet to be standardized. Most authors 
recommend a wide surgical margin of about 1cm. The consensus is a 
close or positive margin while preserving the function is acceptable. 
 
 Radiation therapy 
                Radiation therapy alone or in addition to surgery has been 
reported to give superior local control rates in few series (Spear et al 
and Ballo et al). Nuyttens et al in a review of 22 articles comparing 
surgery and radiation found that local control rates were more with 
combination of surgery and radiation and radiation alone  than for 
surgery alone. These authors recommended that mutilating surgeries 
should be avoided and more conservative approach should be chosen. 
But most of these reviews included only a few numbers of patients and 
patients were chosen for radiation therapy at the discretion of surgeon 
or radiation oncologist. Moreover these articles do not take into 
consideration about the stable phase of disease while measuring the 
response to treatmet. All these factors make most authors recommend 
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surgery as the primary treatment for operable tumors and radiation as 
adjuvant.  Indication for adjuvant radiation has not been standardized 
though most authors would recommend it for recurrent tumors, margin 
positive tumors and multiple tumors(12,14,21,22,24&25). Most series 
recommend a dose of about 50 to 60 Gy.  
 
Systemic therapy 
                The role of cytotoxic, noncytotoxic and hormonal therapy 
has been reviewed recently by Jannis et al. There are no randomized 
control trials which have evaluated the role of various systemic 
therapies for fibromatosis but there are many case series reports on this 
subject(26,27,28,31,33,34&35) . Agents used as systemic therapy includes 
sulindac, tamoxifen, combination chemotherapy with methotrexate and 
vinblastine or doxorubicin based chemotherapy. Indication for 
systemic therapy are 
    1.To avoid mutilating surgery,  
  2.Inoperable mesenteric and retroperitoneal tumors and 
  3.Recurrent tumors.  
Optimal duration of these treatments should be based on clinical 
benefit and tolerance.     
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               To conclude surgery is the standard of care in managing 
fibromatosis, radiation is an useful adjuvant and medical management 
can be given a try before proceeding with mutilating surgey or 
amputation 
 
Updates in the management of Desmoid tumors and our 
experience 
 
     Recently, many articles coming up describing a stable phase in the 
natural course of disease, ranging from 6 months to 36 months. After 
the stable phase, the tumor either increases or decreases in size. This 
will have a major impact on the treatment rendered and assessment of 
response to treatment in future. 
        Whether performing the surgery during the stable phase of the 
disease will reduce the recurrence is to be investigated. Exploring the 
possibility of inducing and maintaining the disease in stable phase 
through systemic therapy will have to be seen 
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Conclusion 
            Demographic trend in India might be different from what is 
reported in the western literature with more incidences in male sex and 
pediatric age group. Recurrences after surgery alone can be quite 
high(40% in our series).  Positive margin & recurrent tumors were 
found to be adverse prognostic factor for recurrence in our series. Even 
in negative margin the recurrence rate was high this we believe is due 
to multicentricity of the lesion.  Addition of radiation provides good 
local control but should be used with diligence as most of the 
recurrences are surgically salvageable and these tumors occur in young 
patients with long life expectancy. The role of systemic therapy 
including Tamoxifen needs further evaluation. 
           Aggressive fibromatosis is an enigma occupying the twilight 
zone between benign and malignant behavior. There are considerable 
lacunae in our knowledge regarding the natural course of the disease. 
Due to the rarity and slow growing nature of the disease there had not 
been many studies with adequate numbers and follow-up to optimize 
treatment protocol for this tumor. There had never been a randomized 
control study comparing different treatments undertaken anywhere in 
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the world. Multi institutional prospective randomized control trials 
may optimize the treatment protocol for this rare and enigmatic 
disease. 
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Centralisation of ulna a unique limb salvage procedure 
 
Fig 1: Preoperative photo 
 
 
 
Fig 2: Defect after excision 
 
 
 
Fig 3: post operative X ray 
 
Scapulectomy 
 
Fig 1: Pre operative photo 
 
 
 
Fig 2: Intraoperative defect 
 
 
 
Fig 3: Post operative picture 
 
 
